MannKind

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MannKind and other ETFs, options, and stocks.

About MNKD

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501.

CEO

Michael E. Castagna

CEOMichael E. Castagna

Employees

414

Employees414

Headquarters

Danbury, Connecticut

HeadquartersDanbury, Connecticut

Founded

1991

Founded1991

Employees

414

Employees414

MNKD Key Statistics

Market cap

1.19B

Market cap1.19B

Price-Earnings ratio

-94.81

Price-Earnings ratio-94.81

Dividend yield

—

Dividend yield—

Average volume

1.90M

Average volume1.90M

High today

$4.49

High today$4.49

Low today

$4.39

Low today$4.39

Open price

$4.45

Open price$4.45

Volume

386.58K

Volume386.58K

52 Week high

$5.75

52 Week high$5.75

52 Week low

$3.17

52 Week low$3.17

MNKD News

Simply Wall St 4h

Analysts Expect MannKind Corporation To Breakeven Soon - Simply Wall St

We feel now is a pretty good time to analyse MannKind Corporation's ( ) business as it appears the company may be on the cusp of a considerable accomplishment....

TipRanks 3d

MannKind to proceed with Phase 1 Nintedanib Dpi (Mnkd-201) study

MannKind announced that it will proceed with a first-in-human Phase 1 study of nintedanib DPI (MNKD-201) for pulmonary fibrotic diseases, including idiopathic p...

Seeking Alpha 4d

MannKind rises as FDA advances rare lung disease therapy to Phase 3 trial

MannKind (NASDAQ:MNKD) shares rose 13% premarket on Monday after the U.S. drug regulator cleared its clofazimine inhalation suspension (MNKD 101) for a Phase 3...